ETR:BIO Biotest Aktiengesellschaft (BIO) Stock Price, News & Analysis €40.20 0.00 (0.00%) As of 06/10/2025 Add Compare Share Share Stock Analysis Stock Analysis About Biotest Aktiengesellschaft Stock (ETR:BIO) Get BIO alerts:Sign Up Key Stats Today's Range€40.20▼€40.2050-Day Range€40.20▼€40.2052-Week Range€40.40▼€43.40Volume19 shsAverage Volume1,927 shsMarket Capitalization€795.56 millionP/E Ratio9.69Dividend Yield0.10%Price TargetN/AConsensus RatingN/A Company Overview Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infection; Fovepta for immunoprophylaxis of hepatitis B in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, including neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B immunoglobulins. In addition, it provides Albiomin and Biseco to restore and maintain circulating blood volume; Cofact for deficiency of coagulation factors; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft is a subsidiary of Grifols, S.A. Read More Receive BIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biotest Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BIO Stock News HeadlinesEQS-News: Biotest AG: Biotest's positive Ergebnisse der Phase III-Studie zu Fibrinogen wurden in der Fachzeitschrift "The Lancet's eClinicalMedicine" veröffentlichtAugust 12, 2026 | finanznachrichten.deEQS-News: Biotest AG: Biotest steigert Umsatz im ersten Halbjahr 2024 um 35% auf 372 Mio. EuroAugust 11, 2026 | finanznachrichten.deGet your evenings backThe Instant Scanner delivers the night's qualifying setups with exact buy prices and defined exits, in minutes. No hours of flipping through charts, no second-guessing patterns. It's built for traders who want the result without the ritual: a short list and your evening back. Black Friday price is $7 versus the regular $247. One payment covers a full year, with no re-bills.November 21 at 1:00 AM | Profits Run (Ad)Nachrichten»EQS-News: Biotest AG: Biotest steigert Umsatz in den ersten 9 Monaten um 4,5% auf 523 Mio. EuroAugust 8, 2026 | finanznachrichten.deEQS-News: Biotest AG steigert den Umsatz um 6% im Geschäftsjahr 2024August 4, 2026 | finanznachrichten.deAktien»Nachrichten»BIOTEST AKTIE»EQS-News: Biotest AG: Biotest erhält Zulassung für neues Human Fibrinogen Prufibry in DeutschlandAugust 4, 2026 | finanznachrichten.deBiotest Aktiengesellschaft (BIO3.HM)July 11, 2026 | ca.finance.yahoo.comBiotest Aktiengesellschaft: Widerruf der Zulassung zum regulierten MarktJune 3, 2025 | finanznachrichten.deSee More Headlines BIO Stock Analysis - Frequently Asked Questions How have BIO shares performed this year? Biotest Aktiengesellschaft's stock was trading at €40.20 at the beginning of the year. Since then, BIO shares have increased by 0.0% and is now trading at €40.20. Industry, Sector and Symbol Stock ExchangeETR SectorTechnology Industry Electronic Equipment, Instruments & Components Sub-IndustryElectronic Equipment & Instruments Current SymbolETR:BIO CIKN/A Webwww.biotest.com Phone+49-6103-8010FaxN/AEmployees8,200Year FoundedN/AProfitability EPS (Trailing Twelve Months)€4.15 Trailing P/E Ratio9.69 Forward P/E RatioN/A P/E GrowthN/ANet Income€164.40 million Net Margins3.64% Pretax MarginN/A Return on Equity5.13% Return on Assets8.47% Debt Debt-to-Equity Ratio112.53 Current Ratio5.06 Quick Ratio1.66 Sales & Book Value Annual Sales€628.73 million Price / Sales1.27 Cash Flow€1.30 per share Price / Cash Flow31.04 Book Value€13.41 per share Price / Book3.00Miscellaneous Outstanding Shares19,790,000Free FloatN/AMarket Cap€795.56 million OptionableNot Optionable Beta0.00 Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (ETR:BIO) was last updated on 6/10/2025 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biotest Aktiengesellschaft Please log in to your account or sign up in order to add this asset to your watchlist. Share Biotest Aktiengesellschaft With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.